News Focus
News Focus
icon url

hope4patients

11/19/22 9:03 AM

#535459 RE: sukus #535458

Makes sense. With a benign side effect profile this therapy will be in HIGH demand. Will the company be able to meet demand? That will be the primary question. A BP partner could be the answer to that question…